Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, and will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results. A replay will be available on the company’s Investor Relations website.

Market reaction after 2Q26 earnings date notice: CAI -5.61% in the Jul 16 session

-5.61%

8 alerts

-5.61% Session close to close

-2.2% Trough in 31 min

$4.79B Market Cap

0.6x Rel. Volume

In the Jul 16 session, CAI declined 5.61%, reflecting a notable negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.6% in the session following this news. A sharp decline after this neutral schedul...

Analysis

The stock moved -5.6% in the session following this news. A sharp decline after this neutral scheduling update would deviate from the historically modest 0.92% average move on past earnings-date notices. Given moderate short positioning, a reversal could reflect positioning shifts rather than any new fundamental data.

Key Figures

Earnings release date: August 5, 2026 Webcast time CT: 3:30 p.m. CT Webcast time ET: 4:30 p.m. ET

3 metrics

Earnings release date August 5, 2026 Second quarter 2026 financial results reporting date

Webcast time CT 3:30 p.m. CT Start time for Q2 2026 results webcast

Webcast time ET 4:30 p.m. ET Start time for Q2 2026 results webcast

Previous Earnings date Reports

2 past events · Latest: Apr 20 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Earnings date notice	Neutral	+0.4%	Scheduled 1Q26 results and webcast details for May 7, 2026.
Feb 09	Earnings date notice	Neutral	+1.4%	Announced 4Q25 and full-year 2025 results date and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior earnings date notices for Caris Life Sciences were followed by modestly positive next-day moves, with an average change of 0.92%.

Key Terms

molecular profiling, whole genome sequencing, next-generation sequencing, precision medicine

4 terms

molecular profiling medical

"Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome"

Molecular profiling is a laboratory analysis that reads a patient’s disease at the level of genes, proteins or other molecules to reveal its specific characteristics—think of it as reading the instruction manual for a tumor or condition. For investors, it matters because the results guide which targeted treatments, diagnostics or tests will be used, shaping clinical demand, regulatory approval paths and potential revenue for companies developing precision medicines and companion tests.

whole genome sequencing medical

"Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing)"

Whole genome sequencing is a laboratory method that reads an individual’s complete DNA instruction book, capturing all genetic letters rather than just selected parts. For investors, it matters because it can reveal new ways to diagnose, prevent or treat disease and to develop tests or drugs — like upgrading from a map of a few streets to a full city blueprint — which can create commercial opportunities, influence regulatory pathways and change healthcare costs and demand.

next-generation sequencing medical

"This convergence of next-generation sequencing, AI and machine learning technologies"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

precision medicine medical

"platform for developing the latest generation of advanced precision medicine diagnostic solutions"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026.

Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.

Webcast Details:

Date: Wednesday, August 5, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qs

A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.

About Caris Life Sciences 
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Investor Relations:
IR@CarisLS.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-second-quarter-2026-financial-results-on-august-5-2026-302827124.html

SOURCE Caris Life Sciences

FAQ

When will Caris Life Sciences (NASDAQ: CAI) report Q2 2026 financial results?

Caris Life Sciences will report its second quarter 2026 financial results on Wednesday, August 5, 2026. According to Caris Life Sciences, management will also host a webcast that afternoon to review and discuss the quarterly results with investors and interested stakeholders.

What time is the Caris Life Sciences CAI Q2 2026 earnings webcast on August 5, 2026?

The Caris Life Sciences Q2 2026 webcast starts at 3:30 p.m. CT (4:30 p.m. ET) on August 5, 2026. According to Caris Life Sciences, the live event will review quarterly financial results and will be accessible online via the company’s webcast link.

How can investors access the Caris Life Sciences (CAI) Q2 2026 earnings webcast?

Investors can access the Caris Life Sciences Q2 2026 webcast via a live stream at https://edge.media-server.com/mmc/p/ff8xb4qs. According to Caris Life Sciences, the webcast will cover the company’s second quarter 2026 financial results and related discussion by management.

Will a replay be available for the Caris Life Sciences CAI Q2 2026 results webcast?

Yes, a replay of the Caris Life Sciences Q2 2026 webcast will be available shortly after the call. According to Caris Life Sciences, investors can access this replay in the Investor Relations section of the company’s website at CarisLifeSciences.com.

What does Caris Life Sciences (NASDAQ: CAI) do as a TechBio company?

Caris Life Sciences is a TechBio company developing and commercializing precision medicine solutions using comprehensive molecular profiling and advanced AI. According to Caris Life Sciences, its multimodal clinico-genomic database supports diagnostics for early detection, diagnosis, monitoring, therapy selection, and drug development globally.

Where is Caris Life Sciences headquartered and in which markets does CAI operate?

Caris Life Sciences is headquartered in Irving, Texas, with offices in Phoenix, New York, Cambridge (MA), Tokyo and Basel. According to Caris Life Sciences, the company and its distributor partners provide services in the United States and additional international markets.